American College of Clinical Pharmacy
      Search      Cart
         

BCOP Clinical Session -- Anticoagulation Therapy: Considerations in the Setting of Malignancy

Sunday, October 27, 2019 from 4:00 PM to 6:00 PM EST at 2nd Floor: Gramercy East

Available for 2.00 hours of CPE credit
Activity Number: 0217-9999-19-160-L01-P
Activity Type: An Application-Based Activity

The BCOP Clinical Sessions are part of the professional development program for the recertification of board-certified oncology pharmacists by the Board of Pharmacy Specialties and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP). In order to earn the BCOP recertification credit, participants must attend the session, claim the continuing pharmacy education credit, and then must pass the associated posttest. Access to the BCOP Clinical Sessions posttests will be available on December 17, 2019 at www.accp.com/myaccount to anyone who has purchased access to the BCOP posttests. For participants who have not purchased access to the posttest, access can be purchased until 5:30 p.m. on Tuesday, October 29, at the ACCP Registration Desk. The deadline to submit posttests for these sessions will be June 17, 2020.

Learning Objectives
1. Discuss the suspected pathophysiology and problem of venous thromboembolism in malignancy.
2. Describe current guidance for primary VTE prophylaxis in cancer patients.
3. Analyze existing and emerging literature regarding the application of DOACs in the treatment of venous thromboembolism in malignancy.
4. Assess issues related to DOAC use in malignancy and the impact they have on patient care.
The Acquired Thrombophilia of Malignancy
4:00 PM

Speakers
  • Amy S. Sipe, R.Ph.Speaker: Amy S. Sipe, R.Ph.
    Clinical Pharmacy Specialist, Kansas City VA Medical Center, Kansas City, Missouri
      View Biography

Primary VTE Prophylaxis in Outpatients with Cancer: Ready for primetime?
4:10 PM

Speakers
  • Katerina  Butler, Pharm.D., BCOPSpeaker: Katerina Butler, Pharm.D., BCOP
    Hematology/Oncology Clinical Pharmacist, VA Salt Lake City Healthcare System, Salt Lake City, Utah
      View Biography

The Changing Landscape of Anticoagulation Therapy for Cancer-Associated VTE
4:25 PM

Speakers
The Devil's in the Details: Therapeutic challenges facing the anticoagulated cancer patient.
4:55 PM

Speakers
  • Speaker: Katerina Butler, Pharm.D., BCOP
    Hematology/Oncology Clinical Pharmacist, VA Salt Lake City Healthcare System, Salt Lake City, Utah
      View Biography

Debate: Should DOACs be used to treat cancer-associated VTE in patients with primary GI/GU cancer?
5:25 PM

Speakers
Panel Discussion
5:45 PM